The Alzheimer's disease research group at CABI, focuses on the use of non-invasive MRI to study the effects of pathological accumulations of the protein hallmarks of Alzheimer's disease, amyloid and tau, on brain structure and function. In collaboration with industrial partner, Eli Lilly, the team at CABI have been conducting longitudinal studies of the effects of novel neuroprotective candidates, and using MR readouts to monitor disease progression, and therapeutic effect, long term.
Close